Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 543 Neoplasms 449 Carcinoma, Non-Small-Cell Lung 410 Prostatic Neoplasms 334 Colorectal Neoplasms 315 Lung Neoplasms 261 Multiple Myeloma 229 Neoplasm Metastasis 190 Pancreatic Neoplasms 186 Leukemia, Myeloid, Acute 183 Ovarian Neoplasms 178 Melanoma 147 Squamous Cell Carcinoma of Head and Neck 140 Carcinoma, Hepatocellular 116 Recurrence 115 Head and Neck Neoplasms 114 Carcinoma, Renal Cell 112 Lymphoma 111 Stomach Neoplasms 110 Endometrial Neoplasms 110 Precursor Cell Lymphoblastic Leukemia-Lymphoma 109 Glioblastoma 108 Brain Neoplasms 106 Lymphoma, Non-Hodgkin 105 Uterine Cervical Neoplasms 100 Triple Negative Breast Neoplasms 97 Urinary Bladder Neoplasms 95 Hematologic Neoplasms 91 Leukemia, Lymphocytic, Chronic, B-Cell 88 Lymphoma, Large B-Cell, Diffuse 84

Interventions

Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × 30 days × Clear all

NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡